AI Article Synopsis
Article Abstract
Recently, mesenchymal stem cells (MSCs) were reported to migrate to tumor stroma as well as injured tissue. We examined the role of human MSCs in tumor stroma using an orthotopic nude mice model of KM12SM colon cancer. In in vivo experiments, systemically injected MSCs migrated to the stroma of orthotopic colon tumors and metastatic liver tumors. Orthotopic transplantation of KM12SM cells mixed with MSCs resulted in greater tumor weight than did transplantation of KM12SM cells alone. The survival rate was significantly lower in the mixed-cell group, and liver metastasis was seen only in this group. Moreover, tumors resulting from transplantation of mixed cells had a significantly higher proliferating cell nuclear antigen labeling index, significantly greater microvessel area and significantly lower apoptotic index. Splenic injection of KM12SM cells mixed with MSCs, in comparison to splenic injection of KM12SM cells alone, resulted in a significantly greater number of liver metastases. MSCs incorporated into the stroma of primary and metastatic tumors expressed α-smooth muscle actin and platelet-derived growth factor receptor-β as carcinoma-associated fibroblast (CAF) markers. In in vitro experiments, KM12SM cells recruited MSCs, and MSCs stimulated migration and invasion of tumor cells through the release of soluble factors. Collectively, MSCs migrate and differentiate into CAFs in tumor stroma, and they promote growth and metastasis of colon cancer by enhancing angiogenesis, migration and invasion and by inhibiting apoptosis of tumor cells.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1002/ijc.25440 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Umbilical cord mesenchymal stromal cells in serum-free defined medium display an improved safety profile.
Stem Cell Res Ther
December 2023
Key Laboratory of Biomedical Information Engineering of the Ministry of Education, School of Life Science and Technology, Xi'an Jiaotong University, Xi'an, 710049, People's Republic of China.
Background: Safety evaluations in preclinical studies are needed to confirm before translating a cell-based product into clinical application. We previously developed a serum-free, xeno-free, and chemically defined media (S&XFM-CD) for the derivation of clinical-grade umbilical cord-derived MSCs (UCMSCs), and demonstrated that intraperitoneal administration of UCMSCs in S&XFM-CD (UCMSC) exhibited better therapeutic effects than UCMSCs in serum-containing media (SCM, UCMSC). However, a comprehensive investigation of the safety of intraperitoneal UCMSC treatment should be performed before clinical applications.
View Article and Find Full Text PDFFunctional Proteomics Characterization of the Role of SPRYD7 in Colorectal Cancer Progression and Metastasis.
Cells
October 2023
Chronic Disease Programme (UFIEC), Instituto de Salud Carlos III, 28220 Madrid, Spain.
SPRY domain-containing protein 7 (SPRYD7) is a barely known protein identified via spatial proteomics as being upregulated in highly metastatic-to-liver KM12SM colorectal cancer (CRC) cells in comparison to its isogenic poorly metastatic KM12C CRC cells. Here, we aimed to analyze SPRYD7's role in CRC via functional proteomics. Through immunohistochemistry, the overexpression of SPRYD7 was observed to be associated with the poor survival of CRC patients and with an aggressive and metastatic phenotype.
View Article and Find Full Text PDFMET kinase inhibitor reverses resistance to entrectinib induced by hepatocyte growth factor in tumors with NTRK1 or ROS1 rearrangements.
Cancer Med
March 2023
Division of Medical Oncology, Cancer Research Institute, Kanazawa University, Kanazawa, Japan.
Background: Entrectinib is an effective drug for treating solid tumors with NTRK gene rearrangement and non-small cell lung cancer (NSCLC) with ROS1 gene rearrangement. However, its efficacy is limited by tolerance and acquired resistance, the mechanisms of which are not fully understood. The growth factors produced by the tumor microenvironment, including hepatocyte growth factor (HGF) produced by tumor-associated fibroblasts, critically affect the sensitivity to targeted drugs.
View Article and Find Full Text PDFMetabolic Reprogramming Helps to Define Different Metastatic Tropisms in Colorectal Cancer.
Front Oncol
July 2022
Functional Proteomics Unit, Chronic Disease Programme, UFIEC, Instituto de Salud Carlos III, Madrid, Spain.
Approximately 25% of colorectal cancer (CRC) patients experience systemic metastases, with the most frequent target organs being the liver and lung. Metabolic reprogramming has been recognized as one of the hallmarks of cancer. Here, metabolic and functional differences between two CRC cells with different metastatic organotropisms (metastatic KM12SM CRC cells to the liver and KM12L4a to the lung when injected in the spleen and in the tail vein of mice) were analysed in comparison to their parental non-metastatic isogenic KM12C cells, for a subsequent investigation of identified metabolic targets in CRC patients.
View Article and Find Full Text PDFInhibition of EGFR and MEK surmounts entrectinib resistance in a brain metastasis model of NTRK1-rearranged tumor cells.
Cancer Sci
July 2022
Division of Medical Oncology, Cancer Research Institute, Kanazawa University, Kanazawa, Japan.
Article Synopsis
- TRK inhibitors are effective for patients with NTRK gene fusions, but resistance can develop, particularly with mutations like NTRK1-G595R.
- The study found that M3B tumor cells, which had the NTRK1-G595R mutation, were resistant to repotrectinib due to ERK reactivation linked to EGFR activation.
- Combining repotrectinib with an EGFR inhibitor and a MEK inhibitor showed promise in overcoming this resistance both in lab tests and a brain metastasis model.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!